Application of Serum Bile Acid Profile in the Diagnosis of Gastric Cancer

NCT06031779 | Completed

• 1 other identifier: KY20232258-C-1
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

In this study, the composition and level of serum bile acids in patients with gastric cancer and non-gastric cancer were analyzed by detecting the serum bile acid profile, so as to develop new serological diagnostic methods for early diagnosis and treatment of gastric cancer.

Conditions

Gastric Cancer

Keywords

serum bile acid; biomarker

Outcome Measures

Primary Outcomes (1)

• serum bile acid profile before treatment

  1 month

Secondary Outcomes (1)

• concentration of serum tumor markers before treatment

  1 month

Study Arms (2)

gastric cancer

non-gastric cancer

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients attending Xijing Hospital and Patients included in the biospecimen bank

You may qualify if:

• Age between 18-70, both gender;
• The gastric cancer group was early gastric cancer or advanced gastric cancer diagnosed by endoscopic examination and pathological biopsy. The non-gastric cancer group included patients without gastric lesions, superficial gastritis, chronic atrophic gastritis, intestinal metaplasia or dysplasia diagnosed by gastroscopy or pathological biopsy;
• Informed consent was obtained.

You may not qualify if:

• The patients have diseases that affect bile acid metabolism, such as liver cirrhosis, gallstones or inflammatory bowel disease, Behcet's disease, etc;
• Due to other diseases, the patient took drugs affecting bile acid metabolism, such as cholestyramine, anti-inflammatory Lidan tablets, Danshu capsules, ursodeoxycholic acid, obticholic acid, Schisandrin B, tanshinone ⅡA, Yinzhihuang, etc;
• Pregnant women;
• Primary tumors of other systems were diagnosed;
• Those with poor physiopathological conditions, such as chronic kidney disease requiring long-term dialysis;
• Patients with mental illness;
• Patients who have received radiotherapy or surgery previously;
• Those with poor adherence or difficult to follow up.

Sponsors & Collaborators

• Xijing Hospital of Digestive Diseases: lead

Study Sites (1)

Xijing Hosipital of Digestive Disease

Xi'an, Shaanxi, 710032, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

serum

MeSH Terms

Conditions

Stomach Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Study Officials

• Yongquan Shi, PhD

  Xijing Hpsipital of Digestive Disease

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator,Clinical Professor

Study Record Dates

• First Submitted: September 3, 2023
• First Posted: September 11, 2023
• Study Start: May 1, 2023
• Primary Completion: May 1, 2024
• Study Completion: July 1, 2024
• Last Updated: July 3, 2025

Record last verified: 2025-07

Locations

CN (1)